ClinicalTrials.gg
CompletedNCT01636947KMECUpdated Sep 25, 2018Results posted

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

A Phase 4 interventional study of Aprepitant and Aprepitant Placebo in Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2018-09-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
494
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing aprepitant in Nausea — 1 open to participants now, 1 under way, none of them phase 3. Aprepitant · Nausea.

Enrollment
Largest of 40
494 · median 49
Started
2012
with 1 other
Phase 4
9 of 40
1 open now
Registered
32nd of 40
by date
Lead sponsor
2 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing aprepitant in Nausea, this one has the largest enrollment, is one of 2 that started in 2012, is one of 9 in phase 4, and was the 32nd registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

1 of the 40 studies testing aprepitant in Nausea is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing aprepitant in Nausea, or all of them as a file.
02

Study summary

This is an efficacy and safety study to compare aprepitant with ondansetron for the prevention of nausea and vomiting in the first cycle of moderately emetogenic chemotherapy (MEC) in participants with solid tumors. MECs include a number of commonly used cancer chemotherapeutic drugs including: oxaliplatin-based, irinotecan-based, and carboplatin-based regimens.

The primary hypothesis of this study is that the Aprepitant Regimen is superior to the Control (ondansetron) Regimen with respect to the percentage of participants with No Vomiting Overall (in the 120 hours following initiation of MEC) in participants with solid tumors.

03

Conditions studied

  • Nausea
  • Vomiting

Keywords

  • chemotherapy
  • nausea
  • vomiting
  • emetogenic
  • cancer
  • antiemetics
  • tumor
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed malignant disease
  • Scheduled to receive a single dose of one or more of moderately emetogenic chemotherapeutic agents during Cycle 1
  • (ECOG) performance status of 0 - 2 or score ≥60
  • Predicted life span ≥4 months
  • Laboratory values demonstrating adequate hematologic status
  • Premenopausal females must not be pregnant or lactating and must agree to use effective

Exclusion criteria

Exclusion Criteria:

  • Received chemotherapy within 6 months prior to starting on study drugs
  • Scheduled to receive subsequent treatment due to a response to first or chemotherapy
  • Received an drug within 30 days prior to starting on study drugs
  • Radiation therapy to the abdomen or pelvis in the week prior to starting on study drugs
  • Vomiting in the 24 hours prior to starting on study drugs
  • Active infection (e.g., pneumonia) or any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) except for
  • Known to Aprepitant (EMEND®), Dexamethasone or 5-HT3 receptor antagonists
  • Presentation with gastrointestinal obstruction symptoms
  • Symptomatic primary or central nervous system malignancy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
494 participants (actual)

Study arms

  • Experimental
    Aprepitant Regimen

    Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.

    Drug: Aprepitant · Drug: Ondansetron · Drug: Dexamethasone · Drug: Ondansetron Placebo · Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).

  • Active comparator
    Control Regimen

    Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.

    Drug: Aprepitant Placebo · Drug: Ondansetron · Drug: Dexamethasone · Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).

Interventions

  • Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3

    Also known as: MK-0869, EMEND® PO

  • DrugAprepitant Placebo

    Aprepitant Placebo (PO, QD) on Days 1, 2, and 3

  • Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3

    Also known as: ZOFRAN®

  • Dexamethasone (20 mg or 12 mg, PO) on Day 1

    Also known as: dexamethasone sodium phosphate, dexamethasone acetate, Decadron, Dexasone, Diodex, Hexadrol, Maxidex

  • DrugOndansetron Placebo

    Ondansetron Placebo (PO, BID) on Days 2 and 3

  • DrugRescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).

    Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants With No Vomiting - Overall Stage

    A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC).

    Time frame: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

Secondary outcomes

  1. Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages

    A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.

    Time frame: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

  2. Number of Emetic Events - Overall Stage

    The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented.

    Time frame: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

  3. Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage

    Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: "How much nausea have you had over the last 24 hours?" The left end of the scale (0 mm) was labeled "no nausea," and the right end of the scale (100 mm) is labeled "nausea as bad as it could be." In this study, No Significant Nausea was defined as a VAS nausea rating \<25 mm.

    Time frame: Days 1 to Day 5

  4. Percentage of Participants With No Impact on Daily Life - Overall Stage

    The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, "No Impact" on daily life was defined as an average item score of \>6 on the 7-point scale; a total score \>108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC.

    Time frame: Day 6

  5. Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages

    The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.

    Time frame: Day 1 to Day 5

  6. Percentage of Participants With One or More Clinical Adverse Event

    An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event.

    Time frame: Day 1 through Day 29 (Up to 28 days after first dose of study drug)

  7. Percentage of Participants With No Vomiting - Acute and Delayed Stages

    A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.

    Time frame: Day 1, Day 2 to Day 5

07

Results

Posted Jul 30, 2015

Participant flow

Participant flow — Overall Study
MilestoneAprepitant RegimenControl Regimen
Started244250
Treated242248
Completed232239
Not completed1211
Withdrew: Not treated22
Withdrew: Lost to follow-up40
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject33
Withdrew: Adverse event11
Withdrew: Did not meet eligibility criteria14

Outcome measures

PrimaryThe Percentage of Participants With No Vomiting - Overall Stage

A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC).

Time frame:
Hour 0 on Day 1 to Day 5 (approximately 120 hours)
Reported as:
Number · Percentage of Participants
The Percentage of Participants With No Vomiting - Overall Stage
Percentage of ParticipantsAprepitant RegimenControl Regimen
The Percentage of Participants With No Vomiting - Overall Stage77.272.0
Statistical analysis
  • Aprepitant Regimen vs Control Regimen · Pearson's chi-square test · p = 0.191
SecondaryPercentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages

A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.

Time frame:
Hour 0 on Day 1 to Day 5 (approximately 120 hours)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages
Percentage of ParticipantsAprepitant RegimenControl Regimen
Overall Stage73.470.4
Acute Stage95.897.9
Delayed Stage74.371.2
Statistical analysis
  • Aprepitant Regimen vs Control Regimen · Pearson's chi-square test · p = 0.458
SecondaryNumber of Emetic Events - Overall Stage

The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented.

Time frame:
Hour 0 on Day 1 to Day 5 (approximately 120 hours)
Reported as:
Number · Number of Emetic Events
Number of Emetic Events - Overall Stage
Number of Emetic EventsAprepitant RegimenControl Regimen
Number of Emetic Events - Overall Stage5468
SecondaryPercentage of Participants With No Vomiting and No Significant Nausea - Overall Stage

Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: "How much nausea have you had over the last 24 hours?" The left end of the scale (0 mm) was labeled "no nausea," and the right end of the scale (100 mm) is labeled "nausea as bad as it could be." In this study, No Significant Nausea was defined as a VAS nausea rating \<25 mm.

Time frame:
Days 1 to Day 5
Reported as:
Number · Percentage of Participants
Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage
Percentage of ParticipantsAprepitant RegimenControl Regimen
Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage76.472.4
SecondaryPercentage of Participants With No Impact on Daily Life - Overall Stage

The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, "No Impact" on daily life was defined as an average item score of \>6 on the 7-point scale; a total score \>108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC.

Time frame:
Day 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With No Impact on Daily Life - Overall Stage
Percentage of ParticipantsAprepitant RegimenControl Regimen
Percentage of Participants With No Impact on Daily Life - Overall Stage76.873.8
SecondaryNumber of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages

The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.

Time frame:
Day 1 to Day 5
Reported as:
Number · Percentage of Participants
Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages
Percentage of ParticipantsAprepitant RegimenControl Regimen
Overall Stage84.887.7
Acute Stage98.799.2
Delayed Stage84.888.5
SecondaryPercentage of Participants With One or More Clinical Adverse Event

An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event.

Time frame:
Day 1 through Day 29 (Up to 28 days after first dose of study drug)
Reported as:
Number · Percentage of Participants
Percentage of Participants With One or More Clinical Adverse Event
Percentage of ParticipantsAprepitant RegimenControl Regimen
Percentage of Participants With One or More Clinical Adverse Event56.253.2
SecondaryPercentage of Participants With No Vomiting - Acute and Delayed Stages

A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.

Time frame:
Day 1, Day 2 to Day 5
Reported as:
Number · Percentage of Participants
Percentage of Participants With No Vomiting - Acute and Delayed Stages
Percentage of ParticipantsAprepitant RegimenControl Regimen
Acute Stage95.898.8
Delayed Stage78.572.4

Adverse events

Collected over Up to 28 days after first dose of study drug (Up to 29 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aprepitant Regimen—25/242 (10.3%)87/242 (36%)
Control Regimen—16/248 (6.5%)96/248 (38.7%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventAprepitant RegimenControl Regimen
NeutropeniaBlood and lymphatic system disorders4/2425/248
DyspnoeaRespiratory, thoracic and mediastinal disorders3/2422/248
Febrile neutropeniaBlood and lymphatic system disorders3/2421/248
AstheniaGeneral disorders3/2421/248
PyrexiaGeneral disorders3/2423/248
HyponatraemiaMetabolism and nutrition disorders2/2420/248
ThrombocytopeniaBlood and lymphatic system disorders2/2421/248
Abdominal painGastrointestinal disorders2/2421/248
DiarrhoeaGastrointestinal disorders2/2421/248
IleusGastrointestinal disorders2/2420/248
Most frequent other events
Most frequent other events
EventAprepitant RegimenControl Regimen
Neutrophil count decreasedInvestigations22/24221/248
ConstipationGastrointestinal disorders10/24222/248
NauseaGastrointestinal disorders20/24220/248
MyalgiaMusculoskeletal and connective tissue disorders11/24218/248
DiarrhoeaGastrointestinal disorders14/24217/248
AlopeciaSkin and subcutaneous tissue disorders9/24217/248
HiccupsRespiratory, thoracic and mediastinal disorders15/2426/248
Decreased appetiteMetabolism and nutrition disorders14/24215/248

Baseline characteristics

The Baseline Analysis Population consists of All Treated Participants. Two participants in each treatment group did not receive study drug.

Age, Customized
Age, Customized(Participants)Aprepitant RegimenControl RegimenTotal
20 to 29 years437
30 to 39 years51015
40 to 49 years322860
50 to 59 years7365138
60 to 69 years7477151
≥70 years5465119
Sex: Female, Male
Sex: Female, Male(Participants)Aprepitant RegimenControl RegimenTotal
Female108111219
Male134137271
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kim JE, Jang JS, Kim JW, Sung YL, Cho CH, Lee MA, Kim DJ, Ahn MJ, Lee KY, Sym SJ, Lim MC, Jung H, Cho EK, Min KW. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer. 2017 Mar;25(3):801-809. doi: 10.1007/s00520-016-3463-0. Epub 2016 Nov 8. Erratum In: Support Care Cancer. 2017 May;25(5):1741. doi: 10.1007/s00520-017-3608-9. PubMed 27826874 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Aug 2014, 19 months.

Results were first posted in Jul 2015, 11 months after primary completion.

Of 27 phase 4 interventional studies under Nausea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2012
First posted
Jul 10, 2012
StartActual
Dec 12, 2012
Primary completionActual
Aug 4, 2014
CompletionActual
Aug 4, 2014
Results first posted
Jul 30, 2015
Last update
Sep 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01636947
Responsible party
Sponsor
First posted
Jul 10, 2012
Start date
Dec 12, 2012
Primary completion
Aug 4, 2014
Completion
Aug 4, 2014
Results posted
Jul 30, 2015
Last update
Sep 25, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprepitant

Start the discussion